ESC 365 - CKD-510, A Non-hydroxamic Acid Hdac6 Inhibitor, For Treatment Of Atrial Fibrillation.

ESC Professional Premium Access

CKD-510, A Non-hydroxamic Acid Hdac6 Inhibitor, For Treatment Of Atrial Fibrillation.

Session: Basic and Translational Late-Breaking Science 2

Topic: Antiarrhythmic Pharmacotherapy

Speaker: Doctor B. Lee (Yongin, KR)

Event: ESC Congress 2022

Congress Presentation

Add to my library

About the speaker

Doctor Beom Seob Lee

Chong Kun Dang Pharm., Yongin (Korea (Republic of))

1 presentation

0 follower

3 more presentations in this session

Ventricular Arrhythmic Risk Prediction in Low- and Moderate-risk Populations Using a Single-Lead ECG Heartbeat.

Speaker: Doctor J. Ramirez (Zaragoza, ES)

The PROspective ATHletic Heart (Pro@Heart) study: long-term assessment of the determinants of cardiac remodelling and its clinical consequences in endurance athletes.

Speaker: Assistant Professor G. Claessen (Hasselt, BE)

Precision approaches to defining susceptibility to atrial fibrillation determine risk of cardioembolic stroke.

Speaker: Doctor P. Gajendragadkar (Oxford, GB)

Access the full session

Basic and Translational Late-Breaking Science 2

Speakers: Doctor B. Lee, Doctor J. Ramirez, Assistant Professor G. Claessen, Doctor P. Gajendragadkar

About the event

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources